Randomized Controlled Trial of MRI Target Biopsy: Transrectal vs. Transperineal
Primary Purpose
Prostate Cancer
Status
Unknown status
Phase
Not Applicable
Locations
Saudi Arabia
Study Type
Interventional
Intervention
Trans-rectal MRI targeted Biopsy
Trans-perineal MRI targeted Biopsy
Sponsored by
About this trial
This is an interventional diagnostic trial for Prostate Cancer
Eligibility Criteria
Inclusion Criteria:
- prostate-specific antigen > 4ng/ml
- Palpation is positive
Exclusion Criteria:
- older than 80y
- prostate-specific antigen > 100 ng/ml
Sites / Locations
- King Khalid University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Trans-rectal MRI targeted Biopsy
Trans-perineal MRI targeted Biopsy
Arm Description
Trans-rectal to perform the prostate MRI targeted biopsy The puncture points are at the rectal
Trans-perineal to perform the prostate MRI targeted biopsy The puncture points are at the perineal
Outcomes
Primary Outcome Measures
the rate of positive detections
the rate of positive detections (How many case are Prostate cancer positive)
Secondary Outcome Measures
the incidence rate of each complication
the Incidence of complication rate is the number of complications divided by the number of patients and the number of patients with complications. Complications were separated into those with major or minor sequelae and the proportion of each type that were due to medical error (avoidable).
Full Information
NCT ID
NCT03650153
First Posted
August 27, 2018
Last Updated
March 3, 2020
Sponsor
Princess Al-Johara Al-Ibrahim Cancer Research Center
1. Study Identification
Unique Protocol Identification Number
NCT03650153
Brief Title
Randomized Controlled Trial of MRI Target Biopsy: Transrectal vs. Transperineal
Official Title
Randomized Controlled Trial of MRI Target Biopsy: Transrectal vs. Transperineal
Study Type
Interventional
2. Study Status
Record Verification Date
March 2020
Overall Recruitment Status
Unknown status
Study Start Date
January 1, 2020 (Actual)
Primary Completion Date
December 31, 2020 (Anticipated)
Study Completion Date
December 31, 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Princess Al-Johara Al-Ibrahim Cancer Research Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This prospective study of comparing between Transrectal and transperineal prostate MRI targeted biopsy to provide evidence for clinicians to select the appropriate biopsy approach under different conditions.
Detailed Description
This prospective study of comparing transperineal (TP) prostate MRI targeted biopsy with transrectal (TR) prostate MRI targeted biopsy was aimed to provide evidence for clinicians to select the appropriate biopsy approach under different conditions. TP (n = 75) and TR (n = 75) will be performed randomly for 150 patients who are suspicious of prostate cancer (PCa). The cancer detection rate (CDR), complication rate, visual analog scale (VAS) score, most painful procedure, number of repeated biopsy and additional anesthesia, and operating time (starting from lying down on the operating table to getting up) will be recorded.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prostate Cancer
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
118 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Trans-rectal MRI targeted Biopsy
Arm Type
Active Comparator
Arm Description
Trans-rectal to perform the prostate MRI targeted biopsy The puncture points are at the rectal
Arm Title
Trans-perineal MRI targeted Biopsy
Arm Type
Active Comparator
Arm Description
Trans-perineal to perform the prostate MRI targeted biopsy The puncture points are at the perineal
Intervention Type
Procedure
Intervention Name(s)
Trans-rectal MRI targeted Biopsy
Intervention Description
Trans-rectal biopsy of the prostate: A procedure in which a sample of tissue is removed from the prostate using a thin needle that is inserted through the rectum and into the prostate.
Intervention Type
Procedure
Intervention Name(s)
Trans-perineal MRI targeted Biopsy
Intervention Description
Trans-perineal biopsy of the prostate: The sample is removed with a thin needle that is inserted through the skin of the perineum and into the prostate.
Primary Outcome Measure Information:
Title
the rate of positive detections
Description
the rate of positive detections (How many case are Prostate cancer positive)
Time Frame
1 year
Secondary Outcome Measure Information:
Title
the incidence rate of each complication
Description
the Incidence of complication rate is the number of complications divided by the number of patients and the number of patients with complications. Complications were separated into those with major or minor sequelae and the proportion of each type that were due to medical error (avoidable).
Time Frame
1 year
Other Pre-specified Outcome Measures:
Title
Pain level assessed by visual analogue scale (VAS)
Description
The pain VAS is a unidimensional measure of pain intensity used adult populations.
The pain VAS is a continuous scale comprised of a horizontal (HVAS) or vertical (VVAS) line, usually 10 centimeters (100 mm) in length, anchored by 2 verbal descriptors, one for each symptom extreme. Instructions, time period for reporting, and verbal descriptor anchors have varied widely in the literature depending on intended use of the scale.
Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100.
A higher score indicates greater pain intensity. Based on the distribution of pain VAS scores in postsurgical patients who described their postoperative pain intensity as none, mild, moderate, or severe, the following cut points on the pain VAS have been recommended: no pain (0-4 mm), mild pain (5-44 mm), moderate pain (45-74 mm), and severe pain (75- 100 mm).
Time Frame
1 year
10. Eligibility
Sex
Male
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
prostate-specific antigen > 4ng/ml
Palpation is positive
Exclusion Criteria:
older than 80y
prostate-specific antigen > 100 ng/ml
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Karim H Farhat, PhD
Phone
+966114679748
Email
kfarhat@ksu.edu.sa
First Name & Middle Initial & Last Name or Official Title & Degree
Danny M Rabah, PhD
Phone
+966114679748
Email
drabah@ksu.edu.sa
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
danny M Rabah, FRCS
Organizational Affiliation
Surgery Department and Cancer Research Chair, College of Medicine, King Saud University, Saudi Arabia
Official's Role
Principal Investigator
Facility Information:
Facility Name
King Khalid University Hospital
City
Riyadh
Country
Saudi Arabia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
karim H Farhat, PhD
Phone
14679748
Email
farhatscience@yahoo.fr
First Name & Middle Initial & Last Name & Degree
Danny M Rabah, Professor
First Name & Middle Initial & Last Name & Degree
Karim H Farhat, PhD
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Randomized Controlled Trial of MRI Target Biopsy: Transrectal vs. Transperineal
We'll reach out to this number within 24 hrs